Search research articles
Contact Us
Filters
Showing results (861-870 of 918) with videos related to
Page
of 92
Sort By:
The Lancet. Haematology
|
October 10, 2022
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study
Thomas Martin, Yi Lin, Mounzer Agha, et al.
Blood
|
October 23, 2013
Smoldering multiple myeloma requiring treatment: time for a new definition?
Angela Dispenzieri, A Keith Stewart, Asher Chanan-Khan, et al.
Journal of Bacteriology
|
August 31, 2010
A commensal gone bad: complete genome sequence of the prototypical enterotoxigenic Escherichia coli strain H10407
Lisa C Crossman, Roy R Chaudhuri, Scott A Beatson, et al.
American Journal of Hematology
|
February 24, 2017
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy
Allison Rosenthal, Amylou C Dueck, Stephen Ansell, et al.
Blood
|
December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
Francesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Journal of Medicinal Chemistry
|
June 5, 2007
Pyridazinoquinolinetriones as NMDA glycine-site antagonists with oral antinociceptive activity in a model of neuropathic pain
Thomas M Bare, Dean G Brown, Carey L Horchler, et al.
Intrinsically Disordered Proteins
|
May 19, 2017
What's in a name? Why these proteins are intrinsically disordered: Why these proteins are intrinsically disordered
A Keith Dunker, M Madan Babu, Elisar Barbar, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
April 15, 2021
Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study
Pedro L S Uson, Douglas Riegert-Johnson, Lisa Boardman, et al.
Molecular Pharmaceutics
|
December 9, 2022
NPP-669, a Novel Broad-Spectrum Antiviral Therapeutic with Excellent Cellular Uptake, Antiviral Potency, Oral Bioavailability, Preclinical Efficacy, and a Promising Safety Margin
Elke Lipka, Aaron M Chadderdon, Cheryl C Harteg, et al.
Blood
|
May 5, 2012
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Ravi Vij, Michael Wang, Jonathan L Kaufman, et al.
Page
of 92
Search research articles
Search
Showing results (861-870 of 918) with videos related to
Sort By:
Page
of 92
The Lancet. Haematology
|
October 10, 2022
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study
Thomas Martin, Yi Lin, Mounzer Agha, et al.
Blood
|
October 23, 2013
Smoldering multiple myeloma requiring treatment: time for a new definition?
Angela Dispenzieri, A Keith Stewart, Asher Chanan-Khan, et al.
Journal of Bacteriology
|
August 31, 2010
A commensal gone bad: complete genome sequence of the prototypical enterotoxigenic Escherichia coli strain H10407
Lisa C Crossman, Roy R Chaudhuri, Scott A Beatson, et al.
American Journal of Hematology
|
February 24, 2017
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy
Allison Rosenthal, Amylou C Dueck, Stephen Ansell, et al.
Blood
|
December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
Francesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Journal of Medicinal Chemistry
|
June 5, 2007
Pyridazinoquinolinetriones as NMDA glycine-site antagonists with oral antinociceptive activity in a model of neuropathic pain
Thomas M Bare, Dean G Brown, Carey L Horchler, et al.
Intrinsically Disordered Proteins
|
May 19, 2017
What's in a name? Why these proteins are intrinsically disordered: Why these proteins are intrinsically disordered
A Keith Dunker, M Madan Babu, Elisar Barbar, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
April 15, 2021
Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study
Pedro L S Uson, Douglas Riegert-Johnson, Lisa Boardman, et al.
Molecular Pharmaceutics
|
December 9, 2022
NPP-669, a Novel Broad-Spectrum Antiviral Therapeutic with Excellent Cellular Uptake, Antiviral Potency, Oral Bioavailability, Preclinical Efficacy, and a Promising Safety Margin
Elke Lipka, Aaron M Chadderdon, Cheryl C Harteg, et al.
Blood
|
May 5, 2012
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Ravi Vij, Michael Wang, Jonathan L Kaufman, et al.
Page
of 92